KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Receivables: 2020-2022

Historic Receivables for Recursion Pharmaceuticals (RXRX) over the last 1 years, with Jun 2022 value amounting to $11.7 million.

  • Recursion Pharmaceuticals' Receivables rose 23736.73% to $11.7 million in Q2 2022 from the same period last year, while for Jun 2022 it was $34.4 million, marking a year-over-year change of. This contributed to the annual value of $9.1 million for FY2021, which is 5726.92% up from last year.
  • As of Q2 2022, Recursion Pharmaceuticals' Receivables stood at $11.7 million, which was up 2.48% from $11.4 million recorded in Q1 2022.
  • Recursion Pharmaceuticals' 5-year Receivables high stood at $11.7 million for Q2 2022, and its period low was $49,000 during Q2 2021.
  • Over the past 3 years, Recursion Pharmaceuticals' median Receivables value was $2.3 million (recorded in 2021), while the average stood at $5.0 million.
  • Data for Recursion Pharmaceuticals' Receivables shows a peak YoY surged of 23,736.73% (in 2022) over the last 5 years.
  • Quarterly analysis of 3 years shows Recursion Pharmaceuticals' Receivables stood at $156,000 in 2020, then soared by 5,726.92% to $9.1 million in 2021, then surged by 23,736.73% to $11.7 million in 2022.
  • Its Receivables was $11.7 million in Q2 2022, compared to $11.4 million in Q1 2022 and $9.1 million in Q4 2021.